These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33883257)

  • 21. Glutamine and asparagine activate mTORC1 independently of Rag GTPases.
    Meng D; Yang Q; Wang H; Melick CH; Navlani R; Frank AR; Jewell JL
    J Biol Chem; 2020 Mar; 295(10):2890-2899. PubMed ID: 32019866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation.
    Pollizzi KN; Patel CH; Sun IH; Oh MH; Waickman AT; Wen J; Delgoffe GM; Powell JD
    J Clin Invest; 2015 May; 125(5):2090-108. PubMed ID: 25893604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth.
    Di Malta C; Siciliano D; Calcagni A; Monfregola J; Punzi S; Pastore N; Eastes AN; Davis O; De Cegli R; Zampelli A; Di Giovannantonio LG; Nusco E; Platt N; Guida A; Ogmundsdottir MH; Lanfrancone L; Perera RM; Zoncu R; Pelicci PG; Settembre C; Ballabio A
    Science; 2017 Jun; 356(6343):1188-1192. PubMed ID: 28619945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.
    Ho WS; Wang H; Maggio D; Kovach JS; Zhang Q; Song Q; Marincola FM; Heiss JD; Gilbert MR; Lu R; Zhuang Z
    Nat Commun; 2018 May; 9(1):2126. PubMed ID: 29844427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combinatorial immunotherapy induces tumor-infiltrating CD8
    Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deletion of Cbl-b inhibits CD8
    Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The E3 ubiquitin ligase Peli1 regulates the metabolic actions of mTORC1 to suppress antitumor T cell responses.
    Ko CJ; Zhang L; Jie Z; Zhu L; Zhou X; Xie X; Gao T; Yang JY; Cheng X; Sun SC
    EMBO J; 2021 Jan; 40(2):e104532. PubMed ID: 33215753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes.
    Lee M; Li J; Li J; Fang S; Zhang J; Vo ATT; Han W; Zeng H; Isgandarova S; Martinez-Moczygemba M; Zhou Y; Sun D; Huang Y
    Cancer Res; 2021 Apr; 81(8):1965-1976. PubMed ID: 33589517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
    Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
    Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing a comprehensive solution aimed to disrupt LARS1/RagD protein-protein interaction.
    Raevsky A; Kovalenko O; Bulgakov E; Sharifi M; Volochnyuk D; Tukalo M
    J Biomol Struct Dyn; 2024; 42(2):747-758. PubMed ID: 36995308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
    Bertrand F; Rochotte J; Colacios C; Montfort A; Tilkin-Mariamé AF; Touriol C; Rochaix P; Lajoie-Mazenc I; Andrieu-Abadie N; Levade T; Benoist H; Ségui B
    Cancer Res; 2015 Jul; 75(13):2619-28. PubMed ID: 25977337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leucine-induced localization of Leucyl-tRNA synthetase in lysosome membrane.
    Choi H; Son JB; Kang J; Kwon J; Kim JH; Jung M; Kim SK; Kim S; Mun JY
    Biochem Biophys Res Commun; 2017 Nov; 493(2):1129-1135. PubMed ID: 28882589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction.
    Kim JH; Jung K; Lee C; Song D; Kim K; Yoo HC; Park SJ; Kang JS; Lee KR; Kim S; Han JM; Han G
    Bioorg Chem; 2021 Jul; 112():104907. PubMed ID: 33979735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-2 regulates tumor-reactive CD8
    Liu Y; Zhou N; Zhou L; Wang J; Zhou Y; Zhang T; Fang Y; Deng J; Gao Y; Liang X; Lv J; Wang Z; Xie J; Xue Y; Zhang H; Ma J; Tang K; Fang Y; Cheng F; Zhang C; Dong B; Zhao Y; Yuan P; Gao Q; Zhang H; Xiao-Feng Qin F; Huang B
    Nat Immunol; 2021 Mar; 22(3):358-369. PubMed ID: 33432230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.
    Berezhnoy A; Castro I; Levay A; Malek TR; Gilboa E
    J Clin Invest; 2014 Jan; 124(1):188-97. PubMed ID: 24292708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamin-dependent amino acid endocytosis activates mechanistic target of rapamycin complex 1 (mTORC1).
    Shibutani S; Okazaki H; Iwata H
    J Biol Chem; 2017 Nov; 292(44):18052-18061. PubMed ID: 28808055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential regulation of mTORC1 activation by leucine and β-hydroxy-β-methylbutyrate in skeletal muscle of neonatal pigs.
    Suryawan A; Rudar M; Fiorotto ML; Davis TA
    J Appl Physiol (1985); 2020 Feb; 128(2):286-295. PubMed ID: 31944890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity.
    Myers DR; Abram CL; Wildes D; Belwafa A; Welsh AMN; Schulze CJ; Choy TJ; Nguyen T; Omaque N; Hu Y; Singh M; Hansen R; Goldsmith MA; Quintana E; Smith JAM; Lowell CA
    Front Immunol; 2020; 11():576310. PubMed ID: 33133093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.